Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H29NO2 |
| Molecular Weight | 291.4284 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=CC=CC=C1C2CCCCC2
InChI
InChIKey=ABXHHEZNIJUQFM-UHFFFAOYSA-N
InChI=1S/C18H29NO2/c1-14(2)19-12-16(20)13-21-18-11-7-6-10-17(18)15-8-4-3-5-9-15/h6-7,10-11,14-16,19-20H,3-5,8-9,12-13H2,1-2H3
Exaprolol is a non-selective antagonist at beta-adrenoceptors exerting antiarrhythmic and local anesthetic activity. It inhibits the inotropic and chronotropic responses. Exaprolol liberates histamine from isolated mast cells and decreases the uptake of extracellular histamine. It acts on mast cells due to the direct and indirect ion exchange mechanism resulted in disproportion between histamine and granule liberation.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Basic ethers of cyclohexylphenols with beta-blocking activity: synthesis and pharmacological study of exaprolol. | 1976 Apr |
|
| Evidence for intracellular histamine liberation in isolated rat mast cells. | 1982 Dec |
|
| Aspects of the cardiovascular pharmacology of exaprolol. | 1984 Sep |
|
| Histamine liberation as a result of nonreceptor interaction. | 1990 Apr |
|
| PET imaging of beta-adrenoceptors in human brain: a realistic goal or a mirage? | 2004 |
|
| Synthesis and preliminary evaluation of (S)-[11C]-exaprolol, a novel beta-adrenoceptor ligand for PET. | 2008 Mar-Apr |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29576
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20866509
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
SUB07491MIG
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
Q4XX54I93R
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
65485
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
C65609
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
55837-19-9
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110841
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
Exaprolol
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
100000081529
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
3706
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY | |||
|
C012969
Created by
admin on Sat Dec 16 16:25:59 GMT 2023 , Edited by admin on Sat Dec 16 16:25:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
